Healis Therapeutics inks collaboration with Massachusetts General Hospital to advance clinical-stage neuroscience research
Overview
Healis Therapeutics, a neurotherapeutics company advancing the treatment of neuropsychiatric and neurodegenerative disease, announced that it has entered into a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).
Focus of Collab
- The collaboration will focus on Healis’ upcoming clinical trial studying the safety and efficacy of CKDB-501A, a BoNT/A neuromodulator, for the treatment of neuropsychiatric conditions, including major depressive disorder (MDD), PTSD, and social anxiety disorder (SAD).
- One of Healis’ strategic priorities is developing the research of Dr. Eric Finzi, who first discovered the efficacy of BoNT/A neuromodulators for neuropsychiatric disorders. “We continue to observe very significant need in the neuropsychiatric patient population,” said Dr. Eric Finzi, co-founder of Healis Therapeutics. ""We are thrilled to work with the world’s leading psychiatry researchers, bringing deep clinical expertise to Healis Therapeutics’ upcoming trial.”
A Revolutionary Clinical Programme
- Healis Therapeutics’ clinical programme in BoNT/A for neuropsychiatry alone has the potential to transform care for what the World Health Organization (WHO) estimates at 280 million patients suffering from major depressive disorder globally. “MDD remains a public health challenge around the world,” said Erik Van Widenfelt, head of clinical trials at Healis Therapeutics. Erik previously worked with Harvard T Chan School of Public Health and alongside major biopharma companies Merck, Roche, Bristol Myers Squibb, Glaxo-Smith Klein, and others.
- “We are thrilled to be at the forefront of this field of research and could not have hoped for a better research partner than Mass. General Hospital (MGH) and Harvard Medical School,” said Sebastian De Beurs, co-founder of Healis Therapeutics.
